Skip to main content

Table 6 Multivariate analysis of risk factors for overall survival

From: The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

Factor Multivariate analysis
HR 95% CI P
Male 1.423 0.481–4.210 0.524
TACE + sorafenib versus sorafenib 0.498 0.278–0.892 0.019
Age 0.984 0.963–1.005 0.140
Tumor number 1.286 1.031–1.604 0.026
Tumor diameter (cm) 1.031 0.965–1.101 0.367
No vascular invasion 0.354 0.183–0.685 0.002
Metastasis 1.365 0.784–2.375 0.271
Child-Pugh stage A 0.308 0.141–0.674 0.003
AFP < 400 ng/mL 0.648 0.373–1.124 0.123
  1. AFP Alpha-fetoprotein, CI confidence interval, HR hazard ratio
\